Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05106907 | Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma | unknown | Phase 1 | 20 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04601935 | A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 34 | Weijun FuOTHER | 1 | Nov 2, 2021 |
| NCT05103917 | A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC | unknown | Phase 1 / Phase 2 | 24 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 2, 2021 | clinicaltrials |
| NCT05100303 | A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT04846439 | Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT00983398 | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors | unknown | Phase 1 / Phase 2 | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT05009966 | Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor | unknown | Phase 1 | 272 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05086666 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | unknown | Phase 1 / Phase 2 | 108 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT05079022 | ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | unknown | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03505944 | Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma(VALERIA) | unknown | Phase 1 / Phase 2 | 59 | Nordic Lymphoma GroupNETWORK | 4 | Oct 13, 2021 | clinicaltrials |
| NCT03843515 | Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction(NeoNivo) | unknown | Phase 1 | 17 | Amsterdam UMC, location VUmcOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT02826837 | LEAC-102 for Advanced Colorectal Cancer | unknown | Phase 1 / Phase 2 | 30 | Taiwan Leader Biotech Corp.INDUSTRY | 0 | Oct 6, 2021 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT02497599 | Intraoperative Dual-modality Imaging in Renal Cell Carcinoma | unknown | Phase 1 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT05054465 | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL(ITALLI001) | unknown | Phase 1 / Phase 2 | 48 | Israeli Medical AssociationOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT00293475 | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 81 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05020639 | A Study of TQB3820 in Patients With Hematological Malignancies | unknown | Phase 1 | 116 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 21, 2021 | clinicaltrials |
| NCT04731038 | Combination Therapy for First Line Treatment of Advanced Cervical Cancer | unknown | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT05047276 | Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma(PULSE-UM) | unknown | Phase 1 / Phase 2 | 16 | José María Piulats RodríguezOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT02948348 | Study to Nivolumab Following Preoperative Chemoradiotherapy | unknown | Phase 1 / Phase 2 | 90 | Takayuki YoshinoOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT04622956 | GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide | unknown | Phase 1 / Phase 2 | 47 | University of Sao Paulo General HospitalOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT02929290 | Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC | unknown | Phase 1 | 80 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 13, 2021 | clinicaltrials |
| NCT05042336 | The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC | unknown | Phase 1 / Phase 2 | 49 | Sichuan UniversityOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT02330367 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC | unknown | Phase 1 / Phase 2 | 368 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Sep 10, 2021 | clinicaltrials |
| NCT05038696 | ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.(ALaCART) | unknown | Phase 1 | 40 | National University Hospital, SingaporeOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT05039658 | Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) | unknown | Phase 1 | 50 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT04061863 | Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer(KORNELIA) | unknown | Phase 1 / Phase 2 | 90 | Seoul National University HospitalOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT05035914 | Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer | unknown | Phase 1 / Phase 2 | 94 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT03720457 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT03798509 | Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT05028478 | A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 164 | Curon Biopharmaceutical (Australia) Co Pty LtdINDUSTRY | 0 | Aug 31, 2021 | clinicaltrials |
| NCT03462212 | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination(MITO25) | unknown | Phase 1 / Phase 2 | 290 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT05021770 | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | unknown | Phase 1 / Phase 2 | 29 | Huiqiang HuangOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT05020925 | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04526470 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | unknown | Phase 1 / Phase 2 | 55 | Seoul National University Bundang HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04687657 | Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia | unknown | Phase 1 | 20 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04928625 | A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer | unknown | Phase 1 | 75 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 24, 2021 | clinicaltrials |
| NCT05013268 | Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma(TiTanec) | unknown | Phase 1 | 15 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04615312 | A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors | unknown | Phase 1 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05016544 | Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05008861 | Gut Microbiota Reconstruction for NSCLC Immunotherapy | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT03374007 | Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma(GB226) | unknown | Phase 1 | 72 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02305186 | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer(UVA-PC-PD101) | unknown | Phase 1 / Phase 2 | 68 | Craig L Slingluff, JrOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT05001412 | Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC | unknown | Phase 1 | 36 | Zhou ChengzhiOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04979663 | GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 10 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04990063 | Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 20 | suhaichuanOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04988191 | Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer | unknown | Phase 1 / Phase 2 | 44 | Peking UniversityOTHER | 1 | Aug 3, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Nov 4, 2021source: clinicaltrials